- Home
- CLB vs AQST Comparison
CLB vs AQST Comparison
Compare CLB & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- AQST
- Stock Information
- Founded
- CLB 1936
- AQST 2004
- Country
- CLB United States
- AQST United States
- Employees
- CLB N/A
- AQST N/A
- Industry
- CLB
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- AQST Health Care
- Exchange
- CLB Nasdaq
- AQST Nasdaq
- Market Cap
- CLB 482.5M
- AQST 390.4M
- IPO Year
- CLB 1995
- AQST 2018
- Fundamental
- Price
- CLB $12.48
- AQST $5.08
- Analyst Decision
- CLB Hold
- AQST Strong Buy
- Analyst Count
- CLB 2
- AQST 7
- Target Price
- CLB $12.50
- AQST $10.29
- AVG Volume (30 Days)
- CLB 490.5K
- AQST 2.6M
- Earning Date
- CLB 10-22-2025
- AQST 11-03-2025
- Dividend Yield
- CLB 0.32%
- AQST N/A
- EPS Growth
- CLB 23.99
- AQST N/A
- EPS
- CLB 0.62
- AQST N/A
- Revenue
- CLB $517,378,000.00
- AQST $44,132,000.00
- Revenue This Year
- CLB N/A
- AQST N/A
- Revenue Next Year
- CLB $2.23
- AQST $38.71
- P/E Ratio
- CLB $20.36
- AQST N/A
- Revenue Growth
- CLB 0.70
- AQST N/A
- 52 Week Low
- CLB $9.72
- AQST $2.12
- 52 Week High
- CLB $21.83
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- CLB 61.63
- AQST 67.17
- Support Level
- CLB $12.07
- AQST $4.75
- Resistance Level
- CLB $13.21
- AQST $5.60
- Average True Range (ATR)
- CLB 0.47
- AQST 0.29
- MACD
- CLB 0.15
- AQST 0.10
- Stochastic Oscillator
- CLB 71.64
- AQST 72.49
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.